News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dutch Biotech Merus Raises €21.7 Million ($30.7 Million)


1/29/2010 6:42:50 AM

Bookmark and Share

peHUB -- Merus, a biopharmaceutical company located in Utrecht, The Netherlands, announced today that it has closed a €21.7 million ($30.7 million) Series B financing round led by new investors the Novartis Option Fund, Pfizer Inc. (New York), Bay City Capital (San Francisco), and LSP (Life Sciences Partners; Amsterdam). Merus’ seed investor Aglaia Oncology Fund (Bilthoven) also participated in this financing.


comments powered by Disqus
Merus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES